<DOC>
	<DOC>NCT01177098</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with GanfortÂ® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patient has ocular hypertension or glaucoma in both eyes Requires IOPlowering therapy in each eye Active or recurrent eye disease that would interfere with interpretation of study data in either eye History of any eye surgery or laser in either eye within 6 months Required chronic use of other eye medications during the study Anticipated wearing of contact lenses during the study. Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>